Could T-cell immunotherapy be the answer to COVID-19?
Scientists from Singapore have argued that T-cell immunotherapy can be used to combat a range of infectious diseases, including COVID-19.
List view / Grid view
Scientists from Singapore have argued that T-cell immunotherapy can be used to combat a range of infectious diseases, including COVID-19.
A new study has revealed that less than 10 percent of respiratory and intestinal cells are susceptible to SARS-CoV-2 infection and expression of ACE2 receptors is driven by the body's immune response.
Glycomimetics, a novel class of antivirals, prevented influenza, herpes viruses and papillomaviruses from infecting cells in animal models and could show similar efficacy against COVID-19.
A study has shown that the COVID-19 pandemic has resulted in a high level of research donations, making the condition the third most funded disease on average by year.
The developers of a novel method to create immunological assay probes for screening T cells has leveraged their new protocol against COVID-19.
Researchers in the UK have selected nanobodies that bind with high affinity to the Spike protein on the COVID-19 coronavirus, enabling stabilisation for imaging.
A total of 21 COVID-19 research projects have been granted funding by the UK government, including vaccine and therapeutic development.
The visualisation platform is being used to analyse how the SARS-CoV-2 virus causing COVID-19 is evolving and could be used to inform drug design.
Researchers comparing the effects of SARS-CoV-2, SARS-CoV and MERS-CoV in cynomolgus macaques suggest they could be an effective animal model for testing COVID-19 therapeutics.
High-throughput screening of thousands of compounds has revealed several candidates, including lead compound ebselen, with the potential for treating COVID-19.
Researchers who developed modified proteins say this could be used in the fight against COVID-19, by tackling cytokine storms.
An international consortium suggest that the severe symptoms of COVID-19, including Acute Respiratory Distress Syndrome (ARDS), could be caused by Neutrophil Extracellular Traps (NETs).
After screening 300 antibodies, Celltrion has identified the 14 most powerful that could potentially combat the COVID-19 coronavirus.
How has evolution led us to the point where humans are an ideal host for SARS-CoV-2, the virus that causes the COVID-19 coronavirus?
According to a new study, the drug remdesivir is a very potent inhibitor for coronavirus polymerases - demonstrating its potential for combatting COVID-19.